Florian Cabillic

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1055153/publications.pdf

Version: 2024-02-01

35 1,404 19 34 g-index

38 38 38 38 3075

times ranked

citing authors

docs citations

all docs

#	Article	IF	Citations
1	Canine Oral Melanoma Genomic and Transcriptomic Study Defines Two Molecular Subgroups with Different Therapeutical Targets. Cancers, 2022, 14, 276.	3.7	3
2	Interplay between Metabolism Reprogramming and Epithelial-to-Mesenchymal Transition in Cancer Stem Cells. Cancers, 2021, 13, 1973.	3.7	23
3	Prognostic value of somatic focal amplifications on chromosome 30 in canine oral melanoma. Veterinary and Comparative Oncology, 2020, 18, 214-223.	1.8	9
4	Diagnosis of uncommon renal epithelial neoplasms: performances of fluorescence in situ hybridization. Human Pathology, 2019, 92, 81-90.	2.0	6
5	Retrodifferentiation of Human Tumor Hepatocytes to Stem Cells Leads to Metabolic Reprogramming and Chemoresistance. Cancer Research, 2019, 79, 1869-1883.	0.9	39
6	ALK IHC and FISH discordant results in patients with NSCLC and treatment response: for discussion of the question $\hat{a} \in \mathcal{C}$ to treat or not to treat? ESMO Open, 2018, 3, e000419.	4.5	23
7	A stitch in time saves nine: external quality assessment rounds demonstrate improved quality of biomarker analysis in lung cancer. Oncotarget, 2018, 9, 20524-20538.	1.8	26
8	Discovery of Human-Similar Gene Fusions in Canine Cancers. Cancer Research, 2017, 77, 5721-5727.	0.9	22
9	Differential diagnosis of atypical lipomatous tumor/well-differentiated liposarcoma and dedifferentiated liposarcoma: utility of p16 in combination with MDM2 and CDK4 immunohistochemistry. Human Pathology, 2017, 59, 34-40.	2.0	85
10	Targeting RET in Patients With <i>RET</i> -Rearranged Lung Cancers: Results From the Global, Multicenter <i>RET</i> Registry. Journal of Clinical Oncology, 2017, 35, 1403-1410.	1.6	277
11	Clinicopathological characteristics of <i>ROS1-</i> and <i>RET-</i> rearranged NSCLC in caucasian patients: Data from a cohort of 713 non-squamous NSCLC lacking KRAS/EGFR/HER2/BRAF/PIK3CA/ALK alterations. Oncotarget, 2017, 8, 53336-53351.	1.8	37
12	Regulation of Transdifferentiation and Retrodifferentiation byÂlnflammatory Cytokines in Hepatocellular Carcinoma. Gastroenterology, 2016, 151, 607-615.	1.3	39
13	Targeting RET in patients with <i>RET</i> -rearranged lung cancers: Results from a global registry Journal of Clinical Oncology, 2016, 34, 9014-9014.	1.6	8
14	Automation of ALK gene rearrangement testing with fluorescence in situ hybridization (FISH): A feasibility study. Experimental and Molecular Pathology, 2015, 98, 113-118.	2.1	9
15	Incidence of brain metastases in HER2+ gastric or gastroesophageal junction adenocarcinoma. Acta Oncol $ ilde{A}^3$ gica, 2015, 54, 1833-1835.	1.8	12
16	Automated Analysis of $1p/19q$ Status by FISH in Oligodendroglial Tumors: Rationale and Proposal of an Algorithm. PLoS ONE, 2015, 10, e0132125.	2.5	8
17	Parallel FISH and Immunohistochemical Studies of ALK Status in 3244 Non–Small-Cell Lung Cancers Reveal Major Discordances. Journal of Thoracic Oncology, 2014, 9, 295-306.	1.1	144
18	Cytoplasmic PAR-3 protein expression is associated with adverse prognostic factors in clear cell renal cell carcinoma and independently impacts survival. Human Pathology, 2014, 45, 1639-1646.	2.0	23

#	Article	IF	Citations
19	Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer. Journal of Translational Medicine, 2013, 11, 147.	4.4	56
20	Histologic prognostic factors associated with chromosomal imbalances in a contemporary series of 89 clear cell renal cell carcinomas. Human Pathology, 2013, 44, 2106-2115.	2.0	20
21	CRTAM Receptor Engagement by Necl-2 on Tumor Cells Triggers Cell Death of Activated VÎ ³ 9VÎ 2 T Cells. Journal of Immunology, 2013, 190, 4868-4876.	0.8	12
22	A Quantitative Deficiency in Peripheral Blood VÎ ³ 9Vδ2 Cells Is a Negative Prognostic Biomarker in Ovarian Cancer Patients. PLoS ONE, 2013, 8, e63322.	2.5	12
23	Incidence of brain metastases in HER2+ gastric or esogastric junction adenocarcinoma Journal of Clinical Oncology, 2013, 31, 126-126.	1.6	0
24	Sensitization of ovarian carcinoma cells with zoledronate restores the cytotoxic capacity of $\hat{V}^{39}\hat{V}^{2}$ T cells impaired by the prostaglandin E2 immunosuppressive factor: Implications for immunotherapy. International Journal of Cancer, 2012, 131, E449-62.	5.1	13
25	HLA-A*0201-restricted CEA-derived Peptide CAP1 Is Not a Suitable Target for T-cell-based Immunotherapy. Journal of Immunotherapy, 2010, 33, 402-413.	2.4	17
26	Aminobisphosphonate-pretreated dendritic cells trigger successful $\hat{V^{3}9}\hat{V^{2}}$ T cell amplification for immunotherapy in advanced cancer patients. Cancer Immunology, Immunotherapy, 2010, 59, 1611-1619.	4.2	77
27	Immunostimulatory Properties of Dendritic Cells after Leishmania donovani Infection Using an In Vitro Model of Liver Microenvironment. PLoS Neglected Tropical Diseases, 2010, 4, e703.	3.0	10
28	DNAX accessory moleculeâ€1 (CD226) promotes human hepatocellular carcinoma cell lysis by Vγ9VÎ ́2 T cells. European Journal of Immunology, 2009, 39, 1361-1368.	2.9	101
29	Daily regulation of serum and urinary hepcidin is not influenced by submaximal cycling exercise in humans with normal iron metabolism. European Journal of Applied Physiology, 2009, 106, 435-443.	2.5	31
30	$\hat{V^{3}}$ 9 $\hat{V^{2}}$ 7 cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas. Cancer Immunology, Immunotherapy, 2008, 57, 531-539.	4.2	101
31	Activation of tumorâ€specific T cells by dendritic cells expressing the NYâ€ESOâ€1 antigen after transfection with the cationic lipophosphoramide KLN5. Journal of Gene Medicine, 2008, 10, 628-636.	2.8	0
32	Soluble HLAâ€G molecules impair natural killer/dendritic cell crosstalk <i>via</i> inhibition of dendritic cells. European Journal of Immunology, 2008, 38, 742-749.	2.9	82
33	Comparison of the immunomodulatory effects of L. donovani and L. major excreted–secreted antigens, particulate and soluble extracts and viable parasites on human dendritic cells. Vaccine, 2008, 26, 6119-6123.	3 . 8	27
34	Hepatic environment elicits monocyte differentiation into a dendritic cell subset directing Th2 response. Journal of Hepatology, 2006, 44, 552-559.	3.7	35
35	PATTERN OF CYTOKINE EXPRESSION BY RAT LIVER EPITHELIAL CELLS SUPPORTING LONG-TERM CULTURE OF HUMAN CD34+UMBILICAL CORD BLOOD CELLS. Cytokine, 2000, 12, 951-959.	3.2	9